GOURI is an injectable collagen stimulator developed by Dexlevo, composed of 21% polycaprolactone in a fully liquid, particle-free formulation. It diffuses through the deep dermis and stimulates fibroblasts to produce the patient's own collagen, rather than adding volume at the injection site.

How long do GOURI results last?

Approximately 6 to 12 months, based on the polycaprolactone biodegradation window. Repeated treatment may extend duration through cumulative collagen deposition, with considerable individual variation.

How is GOURI different from particle-based PCL fillers?

Particle-based PCL products contain microspheres in a gel carrier, require reconstitution, and primarily add volume at the deposition point. GOURI is fully liquid and particle-free, requires no preparation, diffuses across the dermal plane, and targets skin texture, elasticity, and dermal density rather than volume. Nodule risk from particle aggregation is reported as lower.

When do GOURI results become visible?

Visible change typically begins from about 4 weeks, following the timeline of collagen synthesis rather than the injection itself. Redness resolves within 1 to 2 days, and consolidated improvement is generally seen around 3 months.

Miso Clinic · Clinical Reference

GOURI: liquid polycaprolactone as a collagen stimulator

Q: What are the side effects of GOURI?

Possible effects include swelling, bruising, erythema, transient pain, allergic reaction, and nodules or uneven distribution. Most are transient. Persistent or worsening symptoms require review by the treating clinician.

GOURI is the first fully liquid, particle-free polycaprolactone (PCL) injectable. This reference explains what it is, how it differs from particle-based PCL fillers, what the evidence currently shows, and what patients should expect — including limitations and adverse effects.

Reference article Reading time ~8 min Reviewed 2026 Miso Clinic · Daegu, Korea

Definition

GOURI is an injectable collagen stimulator developed by Dexlevo (Seoul, South Korea), composed of 21% polycaprolactone (PCL) in a fully liquid, particle-free formulation. Unlike particle-based PCL fillers, which add volume at the injection site, GOURI is designed to diffuse through the deep dermis and stimulate fibroblasts to produce the patient's own collagen. It is administered by a physician, typically via cannula across the full face, and the PCL biodegrades over approximately 6–12 months.

Key facts

GOURI at a glance
Product class	Injectable collagen stimulator (biostimulator)
Active material	Polycaprolactone (PCL), 21% concentration
Formulation	Fully liquid; no microspheres or particles
Proprietary technology	CESABP — Collagen Enabled Solubilized Active and Biodegradable Polymer
Manufacturer	Dexlevo, Seoul, South Korea
Primary target	Skin quality — dermal density, elasticity, fine lines
Not primarily for	Volume replacement or facial contouring
Administration	Cannula, deep dermis, multi-vector across the face
Preparation	None — no reconstitution or hydration step
Onset of visible change	Typically from 4 weeks
Biodegradation window	Approximately 6–12 months

Mechanism of action

Polycaprolactone is a biocompatible, bioresorbable polymer with a long history in surgical sutures and medical implants. When injected into the deep dermis, PCL forms a scaffold that the body responds to by activating fibroblasts — the cells responsible for producing collagen.

The PCL itself is gradually broken down and cleared. What remains after resorption is newly synthesized endogenous collagen. This is why the clinical effect is delayed rather than immediate: nothing is being filled, and the visible change follows the timeline of collagen synthesis rather than the timeline of injection.

GOURI's distinguishing property is diffusion. Because the formulation contains no particles, it spreads through the dermal plane rather than remaining concentrated at each deposition point. The manufacturer positions this as the basis for two claimed advantages: broader coverage from a single treatment, and a lower likelihood of particle-aggregation nodules.

Liquid PCL compared with particle-based PCL

Formulation comparison
Property	Particle-based PCL	GOURI (liquid PCL)
Composition	PCL microspheres in a gel carrier	100% liquid, particle-free
Preparation	Reconstitution / hydration required	Ready to use
Main indication	Volume augmentation	Skin texture, elasticity, density
Distribution	Localized to deposition points	Diffuse across the dermal plane
Nodule risk	Comparatively higher	Reported as lower
Delicate areas	More restricted	Periorbital and perioral areas reported as feasible

The practical distinction matters for treatment selection. A patient whose primary concern is midface volume loss is a candidate for a volumizing product; a patient whose primary concern is thinning, crepey, or dull skin across the whole face is a candidate for a diffusing biostimulator. These are different problems, and comparing the two product classes on a single axis of "which is better" is not clinically meaningful.

Evidence

Dexlevo reports completed Phase 1 and Phase 2 clinical trials involving more than 200 participants.

A 2026 study published in an international journal — Liquid-Form Polycaprolactone Injection Enhances Dermal Thickness and Collagen Production in UVB-Induced Photoaging Skin — applied liquid PCL to a UVB-induced photoaging skin model. The study reported a significant increase in dermal thickness, higher collagen density, and recovery of collagen-synthesis-related gene expression. Follow-up at 4, 8, and 12 weeks reported no serious inflammatory response and no granuloma formation.

How to read this evidence

The 2026 study is a photoaging model, not a large randomized controlled trial in a general patient population. It supports the biological plausibility of the mechanism and provides short-term safety signal; it does not establish an expected magnitude of cosmetic improvement for any individual. Independent long-term comparative data against other biostimulators remains limited. Claims of guaranteed results are not supported by the published record.

Candidacy and contraindications

Commonly considered appropriate for

Loss of skin elasticity and dermal thinning
Fine static lines and overall textural dullness
Patients who prefer gradual change over immediate volume
Patients concerned about nodule formation with particle-based products
Patients who cannot accommodate significant downtime

Not appropriate for

Pregnancy or breastfeeding
Current use of immunosuppressants or anticoagulants
Active infection or inflammation at the treatment site
Known hypersensitivity to product components

Candidacy is determined by a physician after in-person assessment. Injection volume and vector are individualized to dermal thickness and the direction of age-related descent; because a liquid formulation spreads, injector technique has a substantial influence on outcome.

Expected timeline

The following reflects a typical course. Individual response varies with age, skin condition, and baseline collagen status.

Day 0

Erythema and mild swellingAn injection response, not a treatment result. Appearance at this point is not predictive.
Days 1–2

Redness largely resolvesMost patients return to normal activity. Makeup resumption per clinician instruction.
Weeks 2–4

First perceptible changeCollagen synthesis phase. Texture and firmness begin to shift. Standard point for review and any additional planning.
Month 3

Consolidated improvementWhere additional sessions were given at 4-week intervals, cumulative effect is most apparent here.
Months 6–12

Resorption and retreatment windowPCL biodegrades and stimulation ends. Maintenance treatment is discussed at this stage.

Aftercare and adverse effects

Avoid for one week

Alcohol
Sauna, steam room, hot baths
Strenuous exercise
Significant UV exposure — sunscreen advised

Adverse effects

As with any injectable procedure, possible effects include swelling, bruising, erythema, transient pain, allergic reaction, and nodules or uneven distribution. Most are transient. Persistent or worsening symptoms require review by the treating clinician. A lower reported nodule risk is not the same as an absence of risk; incidence depends on injection depth, volume, and technique.

Frequently asked questions

How many GOURI sessions are needed?

The manufacturer's baseline protocol is a single session, with one to two optional additional sessions at 4–6 week intervals. Some clinics use a three-session course at 4-week intervals where a larger change is sought. The appropriate number is determined after assessment.

How long do the results last?

Roughly 6–12 months, based on the PCL biodegradation window. Repeated treatment may extend the duration through cumulative collagen deposition, but individual variation is considerable and no fixed figure applies to everyone.

Is GOURI a dermal filler?

It is classified as an injectable implant but functions as a collagen stimulator rather than a volumizing filler. It does not produce immediate volume, and it is not a substitute for hyaluronic acid filler where structural volume is the goal.

How does GOURI compare with Sculptra, Juvelook, or Rejuran?

These products differ in both material and objective. Poly-L-lactic acid products such as Sculptra are primarily volumizing biostimulators. Polynucleotide products such as Rejuran target skin regeneration through a different mechanism. GOURI targets dermal density and texture via diffuse PCL stimulation. Direct head-to-head comparative trials are limited, so selection is generally based on the clinical problem rather than on ranked efficacy.

Is it painful?

Topical anesthetic is applied and a cannula is generally used, which reduces pain and bruising relative to multiple needle punctures. Pain thresholds vary.

Can it be combined with botulinum toxin, filler, or energy-based lifting?

Combination is common, but sequencing and interval matter. Some procedures can be performed on the same day and others require spacing. Full treatment history should be disclosed at consultation.

Will nodules form?

Particle-aggregation nodules are the specific risk that a particle-free formulation is designed to reduce, and the reported incidence is lower. Nodules remain possible depending on injection depth and volume. Operator experience is the most significant modifiable factor.

What does GOURI cost?

Pricing varies by volume administered, treatment area, region, and whether it is combined with other procedures. Advertising of medical procedure pricing is regulated in some jurisdictions, including South Korea; cost is normally provided at consultation.

References

Dexlevo. Why GOURI — product composition, CESABP technology, cannula protocol, and clinical trial summary. gorgeousgouri.com/why_gouri
Liquid-Form Polycaprolactone Injection Enhances Dermal Thickness and Collagen Production in UVB-Induced Photoaging Skin (2026) — dermal thickness, collagen density, and gene expression outcomes in a photoaging model.
Clinical practice guidance on GOURI treatment planning, downtime, aftercare, and contraindications. healingderm.com/guide-to-gouri
Comparative summary of powder-form and liquid-form PCL preparation, nodule risk, and treatment areas. gguni114.co.kr
Procedure duration, onset, and maintenance interval in clinical practice. cheongdamartii.com/treatment/gouri

Author and clinic

This reference was prepared and reviewed by Lee Chi-Hak, MD, director of Miso Clinic in Daegu, South Korea. The clinic carries six collagen boosters across four material classes — liquid PCL (GOURI), polynucleotide (Rejuran), human acellular dermal matrix (Re2O, CellRedM), and calcium hydroxylapatite (Radiesse, DCLASSY) — and selects between them according to which type of ageing the face is showing. How the six differ is set out in Six collagen boosters compared.

Miso Clinic
Director	Lee Chi-Hak, MD
Location	4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu, South Korea (Kyungpook National University Hospital Station, Exit 1)
Telephone	+82 53-428-2700
Hours	Weekdays 11:00–19:00 (lunch 13:00–14:00); Saturday 10:00–16:00; closed Sunday and public holidays
Website	clinicmiso.co.kr
Korean version	고우리(GOURI) 한국어 자료

This article provides general information about a medical aesthetic procedure and does not constitute medical advice, diagnosis, or treatment. Outcomes and adverse effects vary by individual skin condition, age, and underlying health status, and no specific result is guaranteed. Regulatory approval status differs by country. Treatment decisions should be made in consultation with a qualified physician after in-person assessment.